Buprenorphine
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Buprenorphine
- Pharmacist Assessment Report
- Buprenorphine: opioid partial agonist → acute intermittent porphyria
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Buprenorphine: opioid partial agonist → acute intermittent porphyria
One-Sentence Summary
Buprenorphine is an opioid medicine marketed in Australia as a transdermal patch (Norspan). The TxGNN model predicts it may be relevant to acute intermittent porphyria, but the data compiled for this report contain no clinical trials and only 1 publication, a case report on anaesthetic management that does not show therapeutic benefit.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | acute intermittent porphyria |
| TxGNN Prediction Score | 0.9941 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Buprenorphine is an opioid, and from its known drug class it acts as a partial agonist at the mu-opioid receptor. No established mechanistic link to acute intermittent porphyria has been identified.
The only publication retrieved describes the anaesthetic management of a patient who already had acute intermittent porphyria. It concerns perioperative drug safety, not treatment benefit. The high TxGNN score is therefore not supported by clinical or mechanistic evidence, and it should be treated as a model-generated hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8301837 | 1993 | Case report | Masui (Japanese Journal of Anesthesiology) | Anaesthetic management of a woman with suspected acute intermittent porphyria undergoing gynaecological cancer surgery; addresses perioperative safety, not efficacy |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10746N | Norspan | Transdermal patch 40 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records. Major-level interactions in the listed entries include alvimopan, bupropion, morphine, cisapride and dolasetron. Moderate-level interactions include famotidine, hyoscyamine, loperamide, aprepitant, atropine, dexamethasone, clarithromycin and several anticholinergic or laxative agents.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No trial or study evaluates buprenorphine as a treatment for acute intermittent porphyria, and the single publication addresses anaesthetic safety only.
To proceed, the following is needed:
- Mechanism of action data and a plausible mechanistic link to porphyria pathophysiology
- Any preclinical or clinical study directly testing buprenorphine in acute intermittent porphyria
- Review of the safety of buprenorphine in porphyria, based on the TGA Product Information
- Full Product Information warnings and contraindications for Norspan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.